Imu biosciences

Mapping the immune system in unprecedented detail and scale. IMU is at the imu biosciences of accelerating cell therapy drug development processes.

Skip to main content. Published: Jan 24, IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease.

Imu biosciences

.

We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. This includes the management of refractory diseases and the discovery of novel therapeutic targets, imu biosciences.

.

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. Tim is Executive Partner at Abingworth, a leading international life sciences investment group, and brings more than 30 years of international investor and management experience in the life sciences industry. Oliver is a leading immunologist specialising on innate immune cells and their use in immuno-oncology, early research and development to IND. She spent three years in the US, gaining international industry and healthcare experience, as Chief of Staff in a commercial stage molecular diagnostics company and as Entrepreneur in Residence at Duke University. US US Edition.

Imu biosciences

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach.

Edge glasses wwe

Our objective is to spearhead the development of the next generation of advanced diagnostic tools, setting new standards in medical technology and patient care. We believe it is our role to support the visionary entrepreneurs who will invent the future. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. Leveraging our advanced immune analytics platform, we address critical development challenges such as donor selection, product characterisation, and patient stratification and monitoring. Mapping the immune system in unprecedented detail and scale. IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. About Kfund Kfund is a family of funds supporting the best tech entrepreneurs in all their stages multistage while covering all their needs multiproduct , across Southern Europe and Latam. All rights reserved. Oliver is a leading immunologist specialising on innate immune cells and their use in immuno-oncology, early research and development to IND. IMU is pioneering the use of innovative, systems-level immunological approaches for patient monitoring and the early detection of graft rejection. Our focus encompasses the entirety of the patient journey, including early detection, precise patient stratification, and advanced monitoring for responses, toxicity, and potential relapse.

Mapping the immune system in unprecedented detail and scale. IMU is at the forefront of accelerating cell therapy drug development processes. Leveraging our advanced immune analytics platform, we address critical development challenges such as donor selection, product characterisation, and patient stratification and monitoring.

Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. Applying AI-driven data analytics to immunology research crystalised further when COVID emerged, and the team leveraged its technology to understand the human immune response to the virus. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. Published: Jan 24, IMU is founded on the belief that leveraging deep, systems-level immunophenotyping at a population scale, combined with the latest advancements in AI and ML, is essential for unlocking the immense potential of the immune system as a tool in the development of precision immune medicines. We are driven by the belief that in the future, no medical decision will be made without truly understanding a patient's immune system, heralding a new era of precision healthcare. IMU is extending these advanced methodologies to novel research areas, including the study of psychosis, broadening the horizons of medical research and patient care. Learn more. Currently, Molten Ventures is a shareholder in a diverse portfolio of companies including Revolut, Trustpilot, Ledger and Thought Machine. For more information please visit: www. Our objective is to spearhead the development of the next generation of advanced diagnostic tools, setting new standards in medical technology and patient care. Our science the imu platform Learn more. This includes the management of refractory diseases and the discovery of novel therapeutic targets.